ReviewEuropean journal of cancer (Oxford, England : 1990)2024
"Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized tools.
Review in European journal of cancer (Oxford, England : 1990), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Exclusion of patients with brain metastases from early-phase systemic therapy trials: a cross-sectional analysis of eligibility criteria.Journal of neuro-oncology · 2026Article
- Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings.Journal of neuro-oncology · 2026Article
- Review
- Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.Journal of neuro-oncology · 2026Article
- The evolving landscape of brain metastasis: volume II.Trends in cancer · 2026Review
- Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.Neuro-oncology · 2026Review
- Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project.Melanoma management · 2025Review
- Screening for brain metastases in patients with advanced non-small cell lung cancer and an actionable genomic alteration: A structured literature review.Neuro-oncology practice · 2025Review
- Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.British journal of cancer · 2025Article
- Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection.JAMA network open · 2025Article
- Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?Neuro-oncology · 2024Review
- Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
With improved systemic treatment and prolonged survival even with metastatic disease, diagnosing, treating, and monitoring brain metastases has become a central topic in the care of patients with melanoma. Patients with brain metastases from melanoma are typically excluded from pivotal clinical trials. When allowed, inclusion and exclusion criteria are rather selective and do not reflect the larger population of melanoma patients with brain metastases who frequently present with neurological symptoms and signs and require steroid medications. Moreover, the lack of consensus on reporting symptomatic brain involvement complicates the interpretation and implications of trial results for the overall population of patients with melanoma and brain metastasis. Here, we review the evidence regarding brain metastasis from melanoma and discuss the challenges of longitudinal neurological clinical assessments, including tools to capture cognition and quality of life. Finally, we propose the adoption of standardized tools to interpret neurological deficits in patients with melanoma and brain metastases and to assess the neurological status in the context of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.